UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Local Institution, Darlinghurst

Local Institution, Fitzroy

Local Institution, Heidelberg

Local Institution, Clayton

Local Institution, Greenslopes

Local Institution, Adelaide

Local Institution, Fremantle

Weill Cornell Medical College, New York

Local Institution, Marseille

Binghamton Gastroenterology Associates, Binghamton

Lehigh Valley Health Network, Allentown

Inova Fairfax Hospital, Falls Church

Mt Vernon Endoscopy Center, Alexandria

Digestive And Liver Disease Specialists, Norfolk

Duke University Medical Center, Durham

Carolinas Center For Liver Disease, Statesville

Asheville Gastroenterology Associates, Pa, Asheville

Gastrointestinal Specialists Of Georgia, Marietta

Borland-Groover Clinic, Jacksonville

Orlando Immunology Center, Orlando

Miami Research Associates, South Miami

Local Institution, Montpellier

Quality Medical Research Pllc, Nashville

University Hospitals Case Medical Center, Cleveland

Indiana University Health, Indianapolis

Dean Clinic, Madison

University Of Chicago, Chicago

Kansas City Care Clinic, Kansas City

Kansas City Research Institute, Kansas City

Local Institution, Paris

Local Institution, Paris

Advanced Liver Therapies, Houston

Texas Liver Institute, San Antonio

University Of Colorado Denver & Hospital, Aurora

Scripps Clinic, La Jolla

Medical Associates Research Group, San Diego

Local Institution, Créteil

Quest Clinical Research, San Francisco

Local Institution, Calgary

Local Institution, Vancouver

Local Institution, Vancouver

Local Institution, Vancouver

Local Institution, Victoria

Local Institution, Hamilton

Local Institution, Toronto

Local Institution, Montreal

Local Institution, Montreal

Local Institution, Montreal

Local Institution, Nice